A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 2

Conditions

HIV Infections

Treatments

Drug: GW810781

Study type

Interventional

Funder types

Industry

Identifiers

NCT00046332

ITG20001

Details and patient eligibility

About

This study will evaluate the drop in viral load over 10 days of treatment with S-1360 versus placebo in HIV-infected patients who have not previously taken anti-HIV medications.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

No prior HIV medications.
HIV infection with viral load >400-50,000 copies/mL.
CD4 cell count >50 cells/mm.

Exclusion criteria

Patients requiring medications that cannot be interrupted for the duration of the study.
Abnormal ECG or other chronic health conditions as noted on screening physical exam.
Previous participation in an experimental drug trial(s) within 30 days of the screening visit for this study.